Today we take a short break from our AACR conference coverage and look at some creative new research that has its roots in oncology, i.e. antibody drug conjugates (ADCs), while being adapted and adopted for use in microbiology and infectious diseases.  Here at BSB, we have always been attracted to innovative science and technology and this latest project certainly fits that bill.

This is not such a stretch as many may think, after all, advanced cancer patients or those in an ICU  tend to be prone to infectious complications, which can, unfortunately, be lethal.

While this work is currently ongoing in the preclinical setting, it could be something we hear a lot more about in the near future as clinical development rolls out and there is a dramatic impact for patients.

Curious as to what all the fuss is about?

Subscribers can learn more by logging in or you can subscribe via the blue box below: 

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR or COMMUNICATIONS you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.